DUSA gains preliminary injunction against Biofrontera

DUSA Pharmaceuticals, a wholly-owned subsidiary of Sun Pharmaceutical Industries (BSE: 524715), has been granted preliminary injunctive relief by a federal district court prohibiting defendants Germany-based skin cancer specialist Biofrontera (FSE: B8F) and its subsidiaries from using DUSA's confidential and proprietary trade secret information.

Sun Pharma shares ended down 2.23%on Wednesday at 414 rupees on the BSE, while Biofrontera fell as much as 10% to 4.78 euros early afternoon today.

DUSA had filed a lawsuit against the Biofrontera defendants earlier this year in the US District Court for the District of Massachusetts. The lawsuit alleges trade secret misappropriation and patent infringement of DUSA's photodynamic therapy (PDT) patents, US 9,723,991 and US 8,216,289, covering DUSA's product, Levulan Kerastick (aminolevulinic acid HCl) for topical solution, 20% used with DUSA's BLU-U Blue Light Photodynamic Therapy Illuminator.